StockData

CervoMed vs Kiora Pharmaceuticals

CRVO and KPRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CRVO and KPRX compare

CervoMed is the larger company, worth 5.5 times as much as Kiora Pharmaceuticals ($22.7M against $4.1M).

Kiora Pharmaceuticals scores higher on the StockData Score (7 against 5 for CervoMed), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCRVOKPRX
Size and price
Market cap$22.7M$4.1M
Share price$1.50$0.930
Change, 1 year−80.5%−56.9%
Change, 5 years−94.9%−99.8%
Beta (5Y)3.411.65
Employees153,500
StockData Score
Total score57 (better)
Valuation score11
Growth score00
Performance score01 (better)
Health score45 (better)
Dividend score00
Valuation
P/S68.5×–
P/B1.0×0.2× (better)
FCF yield–−209%
Growth
Revenue growth (TTM)−95.7%–
Profitability
Operating margin−9407%–
Net margin−9161%–
Return on equity−108%−56.4% (better)
Return on invested capital–−1374%
Financial health
Debt / equity0.000.00
Current ratio–8.97
Altman Z-score−5.50 (better)−9.82
Piotroski F-score13 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions11.6%25.0%
Held by insiders36.9%3.0%
Insider net buying, 12 months$3.0M–
Short interest, % of float12.7%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.